ID

17190

Description

Lingzhi and Sen Miao San for the Treatment of Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT00432484

Lien

https://clinicaltrials.gov/show/NCT00432484

Mots-clés

  1. 30/08/2016 30/08/2016 -
Téléchargé le

30 août 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :


Aucun commentaire

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Rheumatoid Arthritis NCT00432484

Eligibility Rheumatoid Arthritis NCT00432484

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
fulfilled the 1987 american college of rheumatology (acr) criteria for ra.
Description

Rheumatoid Arthritis

Type de données

boolean

Alias
UMLS CUI [1]
C0003873
the presence of 2 or more swollen or tender joints, based on 28-joint count.
Description

swollen/tender joint count

Type de données

boolean

Alias
UMLS CUI [1]
C0451521
UMLS CUI [2]
C0451530
morning stiffness lasting for 30 minutes.
Description

morning stiffness

Type de données

boolean

Alias
UMLS CUI [1]
C0457086
erythrocyte sedimentation rate (esr) of 28 mm/hour, despite treatment with disease modifying agent including mtx, sulphasalazine, hydroxychloroquine, auranofin or azathioprine were recruited into the study.
Description

erythrocyte sedimentation rate (esr), treatment with disease modifying agent

Type de données

boolean

Alias
UMLS CUI [1]
C1176468
UMLS CUI [2]
C0242708
patients taking glucocorticoids (prednisone < 7.5 mg/day) and/or nonsteroidal antiinflammatory drugs must have been taking a stable dosage for at least 4 weeks before entering the trial and were required to take the same dosage throughout the trial.
Description

glucocorticoids and/or nonsteroidal antiinflammatory drugs, stable dosage

Type de données

boolean

Alias
UMLS CUI [1,1]
C0017710
UMLS CUI [1,2]
C0205360
UMLS CUI [2,1]
C0003211
UMLS CUI [2,2]
C0205360
patients had radiographic erosive diseases.
Description

Bone erosion

Type de données

boolean

Alias
UMLS CUI [1]
C0587240
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who are pregnant or nursing mothers.
Description

pregnant or breast feeding

Type de données

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
severe liver disease (e.g cirrhosis, chronic active hepatitis)
Description

Severe liver disease

Type de données

boolean

Alias
UMLS CUI [1,1]
C0023895
UMLS CUI [1,2]
C0205082
renal impairment (serum creatinine level > 150mmol/l)
Description

serum creatinine

Type de données

boolean

Alias
UMLS CUI [1]
C0201976
known hypersensitivity to herbal medicine
Description

Hypersensitivity to herbal medicine

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0025125

Similar models

Eligibility Rheumatoid Arthritis NCT00432484

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Rheumatoid Arthritis
Item
fulfilled the 1987 american college of rheumatology (acr) criteria for ra.
boolean
C0003873 (UMLS CUI [1])
swollen/tender joint count
Item
the presence of 2 or more swollen or tender joints, based on 28-joint count.
boolean
C0451521 (UMLS CUI [1])
C0451530 (UMLS CUI [2])
morning stiffness
Item
morning stiffness lasting for 30 minutes.
boolean
C0457086 (UMLS CUI [1])
erythrocyte sedimentation rate (esr), treatment with disease modifying agent
Item
erythrocyte sedimentation rate (esr) of 28 mm/hour, despite treatment with disease modifying agent including mtx, sulphasalazine, hydroxychloroquine, auranofin or azathioprine were recruited into the study.
boolean
C1176468 (UMLS CUI [1])
C0242708 (UMLS CUI [2])
glucocorticoids and/or nonsteroidal antiinflammatory drugs, stable dosage
Item
patients taking glucocorticoids (prednisone < 7.5 mg/day) and/or nonsteroidal antiinflammatory drugs must have been taking a stable dosage for at least 4 weeks before entering the trial and were required to take the same dosage throughout the trial.
boolean
C0017710 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0003211 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
Bone erosion
Item
patients had radiographic erosive diseases.
boolean
C0587240 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
pregnant or breast feeding
Item
patients who are pregnant or nursing mothers.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
Severe liver disease
Item
severe liver disease (e.g cirrhosis, chronic active hepatitis)
boolean
C0023895 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
serum creatinine
Item
renal impairment (serum creatinine level > 150mmol/l)
boolean
C0201976 (UMLS CUI [1])
Hypersensitivity to herbal medicine
Item
known hypersensitivity to herbal medicine
boolean
C0020517 (UMLS CUI [1,1])
C0025125 (UMLS CUI [1,2])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial